Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Regeneron Pharmaceuticals recently completed a clinical study titled ‘A Parallel Group Study in Healthy Participants to Quantitate Increases in Subclinical Gastrointestinal Blood Loss Following Administration of Aspirin Alone or in Combination With Rivaroxaban or Factor XI Inhibitors (REGN9933 or REGN7508)’. The study aimed to assess whether the experimental drugs REGN9933 and REGN7508, when combined with aspirin, result in less gastrointestinal blood loss compared to the combination of aspirin and rivaroxaban.
The interventions tested included aspirin alone, aspirin with REGN9933, aspirin with REGN7508, and aspirin with rivaroxaban. REGN9933 and REGN7508 were administered intravenously, while aspirin and rivaroxaban were given orally. The primary goal was to evaluate treatment effects on intestinal bleeding.
The study was designed as a randomized, parallel-group trial with no masking, focusing on treatment outcomes. Participants were randomly assigned to one of the four treatment arms.
The study began on September 30, 2024, and was completed by July 15, 2025. These dates are crucial for understanding the timeline of data collection and analysis.
This update from Regeneron could influence investor sentiment positively, as successful outcomes might enhance Regeneron’s competitive position in the pharmaceutical industry, potentially impacting stock performance. The study’s results could also affect the market dynamics for similar treatments offered by competitors.
The study is now completed, with further details available on the ClinicalTrials portal.